Mobile Gamma Cameras Market Size, Share and Forecast, 2026–2035

Mobile Gamma Cameras Market Overview

The global mobile gamma cameras market is valued at USD 97.60 million in 2025 and is projected to reach USD 181.50 million by 2035, advancing at a compound annual growth rate of 6.40% from 2026 to 2035. Demand is shifting toward compact solid-state systems, procedure-specific cameras and transportable platforms that bring nuclear imaging closer to the patient or fit into smaller clinical spaces.

A mobile gamma camera detects gamma photons emitted by an administered radiopharmaceutical and converts those signals into functional images. Unlike a permanently installed conventional system, a mobile unit can be repositioned within a department, operated in a compact examination room or taken to the bedside, depending on its design. The category includes wheeled single-, dual- and triple-head systems as well as handheld cameras used during surgery or for localized imaging. Full-size fixed SPECT and PET systems are outside the core market unless the product is explicitly designed for relocation or compact mobile deployment.

Mobility alone does not determine purchasing value. Hospitals assess detector sensitivity, spatial and energy resolution, field of view, acquisition speed, collimator options, isotope compatibility, reconstruction software and the ability to clean and maneuver the device. Procurement also depends on shielding requirements, room preparation, service coverage, regulatory clearance, radiopharmaceutical workflow and reimbursement. A compact camera that cannot support the facility’s expected patient mix will not displace a general-purpose system merely because it occupies less space.

The strongest commercial use cases are those in which conventional imaging creates a workflow bottleneck. These include myocardial perfusion imaging in outpatient cardiology, lymphatic mapping and sentinel-node localization, thyroid and parathyroid imaging, renal studies, localized bone or infection imaging and selected bedside examinations. The rise of radioligand therapy is also raising interest in flexible SPECT technologies that can support post-therapy imaging and dosimetry, though not every mobile camera has the energy range, sensitivity or quantitative software required for these tasks.

Key Highlights

• Global revenue is estimated at USD 97.60 million in 2025 and is forecast to reach USD 181.50 million by 2035 at a 6.40% CAGR.
• Triple-head systems lead product revenue with a 43.5% share, reflecting their role in rapid cardiac SPECT and high-throughput outpatient imaging.
• Cardiac imaging accounts for 34% of 2025 sales, while oncology, breast and surgical localization applications are expanding the addressable customer base.
• Hospitals hold 54% of revenue, but ambulatory and specialized imaging providers are increasing purchases of compact systems that require limited room modification.
• North America leads with 38.4% of 2025 revenue; Asia-Pacific is expected to grow fastest as nuclear medicine capacity expands in China, India, Japan and South Korea.
• Cadmium zinc telluride detectors are gaining share because direct-conversion imaging supports compact architecture, higher sensitivity and shorter acquisitions.
• Equipment utilization, isotope supply, reimbursement and local service capability remain decisive adoption constraints.

Market Dynamics

Compact Nuclear Imaging Is Moving Closer to the Point of Care

The principal growth driver is the need to place functional imaging where clinical decisions are made. Transporting fragile, critically ill or postoperative patients to a nuclear medicine suite consumes staff time and may delay care. Bedside-capable and maneuverable systems can reduce this movement in selected cases. Compact cameras also allow cardiology clinics and specialized imaging centers to establish services where a conventional rotating gamma camera would require more floor space, structural work or shielding.

The benefit is most compelling when the device supports a repeatable, high-volume protocol. Dedicated cardiac systems can shorten myocardial perfusion acquisitions and improve throughput without occupying a general-purpose nuclear medicine room. Handheld systems help surgeons locate radiolabeled tissue during sentinel-node or parathyroid procedures. Small-field cameras can verify tracer distribution or examine a localized anatomy. These applications create a clearer return on equipment than an undefined promise of portability.

Solid-State Detectors Are Changing Equipment Design

Cadmium zinc telluride, or CZT, detectors convert gamma photons directly into electrical signals. Their compact form and energy-resolution characteristics allow manufacturers to arrange detectors closer to the patient or around a target organ. This supports smaller footprints, faster protocols and new geometries that are difficult to achieve with traditional sodium iodide scintillation detectors and photomultiplier tubes.

Adoption is not automatic. CZT systems can carry higher acquisition costs, and detector configuration may be optimized for one application rather than whole-body flexibility. Facilities compare the productivity gain with expected procedure volume, service expense and reimbursement. The commercial winner is often the system that improves daily scheduling and diagnostic confidence, not the one with the strongest detector specification in isolation.

Chronic Disease and Theranostics Broaden the Imaging Workload

Cardiovascular disease, cancer, kidney disease and endocrine disorders sustain the core nuclear imaging workload. Growing use of targeted radiopharmaceuticals adds another layer of demand. Theranostic programs need imaging to confirm uptake, evaluate response and, in some protocols, estimate absorbed dose. Compact digital SPECT and SPECT/CT systems can support this expansion when they are cleared for the relevant isotope and provide reliable quantification.

The opportunity is selective because mobile cameras vary widely. A handheld camera intended for surgical localization does not replace a quantitative SPECT/CT platform. Product positioning must state the clinical task, compatible radionuclides, field of view and validation status. Broad claims that group every mobile camera under theranostics can overstate the addressable demand.

Capital Cost and Utilization Restrain Adoption

Hospitals must fund the camera, service contract, quality-control tools, workstations, accessories and staff training. A nuclear imaging program also needs licensed personnel, radiopharmaceutical handling processes and access to isotopes with short, time-sensitive supply chains. Low scan volume can make ownership uneconomic even when the device is easier to install than a conventional system.

Leasing, rental, shared-service and mobile imaging arrangements reduce the initial commitment. Digirad, now part of Catalyst MedTech, markets ownership, lease and rental options for its compact systems. Such models can expand access, but providers still need sufficient patient referrals and payer coverage. Vendors that combine equipment with applications training, service guarantees and utilization planning are better placed to close capital purchases.

Regulation and Evidence Shape the Sales Cycle

Gamma cameras are regulated medical devices and must satisfy market-specific requirements before commercial use. New detector architectures, software changes and AI-based reconstruction may require additional documentation or clearance. Hospitals also ask for clinical comparisons, image-quality evidence, reliability data and cybersecurity support. An investigational camera can generate scientific interest long before it produces commercial revenue.

Reimbursement is equally important. Payment is generally tied to the clinical nuclear medicine procedure rather than the mobility of the camera. A new device therefore needs to improve throughput, broaden access, avoid patient transport or reduce installation burden within the existing reimbursement pathway. Technology that adds capital cost without changing workflow or diagnostic value faces a longer adoption cycle.

Market Scope and Forecast

Market Segmentation Analysis

By Product Type

Triple-head mobile gamma cameras generated 43.5% of 2025 revenue, equal to USD 42.46 million. Their leading position reflects fast cardiac acquisition, broad angular sampling and high patient throughput. Dedicated cardiac configurations are particularly attractive to outpatient practices because upright or open designs can be more comfortable for patients and occupy less space than traditional rotating systems.

Double-head mobile gamma cameras accounted for 26.5%, or USD 25.86 million. They remain relevant for facilities seeking a balance between general-purpose flexibility, acquisition speed and capital cost. Single-head systems held 17%, equal to USD 16.59 million, supported by lower-cost deployments and localized imaging tasks. Handheld mobile gamma cameras represented 13%, or USD 12.69 million. Although smaller in current revenue, handheld devices are expected to record the strongest unit growth as surgical guidance, bedside imaging and targeted small-field applications mature.

By Detector Technology

Solid-state cameras based mainly on CZT detectors captured 58% of 2025 revenue, valued at USD 56.61 million. Their share is supported by compact detector geometry, direct conversion, energy resolution and the ability to position detectors close to the anatomy. Solid-state technology is strongest in cardiac systems and emerging compact 3D configurations.

Scintillation cameras held 42%, or USD 40.99 million. Sodium iodide detector technology remains clinically familiar, supports broad radionuclide use and benefits from an installed service base. This segment will retain demand in cost-sensitive and general-purpose settings, but its revenue share is expected to decline as solid-state products become more accessible and application evidence expands.

By Indication

Cardiac imaging was the largest indication in 2025 with 34% of revenue, equal to USD 33.18 million. Dedicated myocardial perfusion systems benefit from repeatable protocols and high outpatient volumes. Oncology and breast imaging together represented 21%, or USD 20.50 million, reflecting sentinel-node mapping, lesion localization and selected molecular breast applications. Brain imaging held 12%, equal to USD 11.71 million, while renal imaging accounted for 10%, or USD 9.76 million.

Hepatobiliary and gastrointestinal imaging generated 9%, or USD 8.78 million. Thyroid, parathyroid, bone, infection and other applications supplied the remaining 14%, equal to USD 13.66 million. The mix will evolve as portable cameras receive broader clinical validation, but small field of view and application-specific collimation will keep many devices concentrated in a limited number of indications.

By End User

Hospitals accounted for 54% of 2025 revenue, valued at USD 52.70 million. They operate the broadest range of nuclear medicine studies and have the staffing, radiation-safety infrastructure and referral networks needed to use the equipment. Specialized clinics and diagnostic imaging centers held 21%, or USD 20.50 million. This segment favors compact systems that fit existing rooms and can support focused cardiac, endocrine or oncology workflows.

Ambulatory surgical centers represented 15%, equal to USD 14.64 million, with demand linked to intraoperative localization and selected point-of-care procedures. Cancer research institutes and academic centers held 10%, or USD 9.76 million. Their commercial importance exceeds their revenue share because they validate new cameras, test radionuclides and influence broader clinical adoption.

Regional and Country-Level Analysis

North America

North America led with 38.4% of global revenue in 2025, equal to USD 37.48 million. The United States represented 33.0% of the global market, or USD 32.21 million, supported by outpatient nuclear cardiology, a large installed base, clinical research and established equipment leasing and mobile-service models. Canada contributed 4.1%, or USD 4.00 million, while Mexico held 1.3%, or USD 1.27 million.

The region’s replacement opportunity centers on solid-state cardiac cameras, compact systems for smaller facilities and digital platforms used in theranostic programs. Sales cycles remain sensitive to procedure reimbursement, isotope availability and capital budgets. U.S. buyers also require FDA clearance for commercial use; investigational status limits a product to research pathways until regulatory requirements are met.

Europe

Europe accounted for 29.0% of 2025 revenue, valued at USD 28.30 million. Germany held 6.5% of global revenue, or USD 6.34 million, followed by the United Kingdom at 5.2%, or USD 5.08 million, and France at 4.8%, or USD 4.68 million. Italy and Spain together represented 5.0%, equal to USD 4.88 million, while the rest of Europe contributed 7.5%, or USD 7.32 million.

European demand benefits from nuclear medicine expertise, academic research networks and active development of portable imaging technology. Procurement is fragmented by national reimbursement and hospital tender systems. Compliance under the European medical-device framework, availability of notified-body capacity and post-market evidence can affect launch timing. Compact products that lower installation requirements have an advantage in older hospital buildings where space and structural modification are difficult.

Asia-Pacific

Asia-Pacific held 24.5% of 2025 revenue, equal to USD 23.91 million, and is forecast to grow faster than all other regions through 2035. Japan represented 7.0% of the global market, or USD 6.83 million, reflecting an advanced imaging system, an aging population and demand for compact equipment in space-constrained facilities. China held 6.5%, or USD 6.34 million, while India accounted for 3.8%, or USD 3.71 million. South Korea contributed 3.2%, or USD 3.12 million, and the remaining regional markets supplied 4.0%, or USD 3.90 million.

Growth depends on nuclear medicine department expansion, local device registration, isotope logistics and trained technologists. Japan and South Korea favor high-performance compact systems, while China and India offer larger long-term unit potential across hospital tiers. Local service networks and uptime guarantees will be as important as detector technology because equipment downtime can disrupt time-sensitive radiopharmaceutical schedules.

Latin America

Latin America generated 4.8% of 2025 revenue, equal to USD 4.68 million. Brazil held 2.7% of the global market, or USD 2.64 million, and Mexico is included within North America in this report. Argentina and other Latin American countries contributed 2.1%, or USD 2.05 million. Compact and refurbished equipment can help providers expand access, but exchange-rate volatility, import costs, maintenance coverage and isotope distribution constrain procurement.

Middle East and Africa

The Middle East and Africa accounted for 3.3% of 2025 revenue, valued at USD 3.22 million. Gulf countries, Türkiye, Israel and South Africa form the main demand centers. New specialty hospitals and oncology programs create opportunities for compact nuclear imaging, while limited radiopharmacy access and shortages of trained staff restrict adoption elsewhere. Distributor capability and multi-year service support are essential when manufacturers lack direct regional operations.

Competitive Landscape

The market combines large imaging companies, specialist nuclear medicine manufacturers and emerging portable-camera developers. Key competitive variables are detector performance, approved clinical applications, installation needs, service response, software, collimator range and financing. Major participants include Catalyst MedTech’s Digirad business, DDD-Diagnostic A/S, Spectrum Dynamics Medical, MIE America, LabLogic Systems, Crystal Photonics, GAEDE Medizinsysteme, Mediso, Oncovision and Serac Imaging Systems. GE HealthCare competes broadly in nuclear medicine, although not every system in its portfolio meets the strict mobile definition used in this report.

Catalyst MedTech - Digirad

Digirad’s portfolio includes the Cardius X-ACT+ triple-head cardiac SPECT system, Cardius XPO and Ergo general-purpose camera. The X-ACT+ combines three solid-state detector heads with integrated fluorescence attenuation correction, upright imaging and a footprint designed for a standard examination room. Its commercial positioning emphasizes rapid myocardial perfusion imaging, limited site preparation and flexible ownership, lease or rental models. Digirad’s established service capability and installed cardiac base are important competitive assets in North America.

DDD-Diagnostic A/S

DDD-Diagnostic specializes in gamma-camera and nuclear medicine systems, including compact and mobile configurations. The company competes through application flexibility, configurable detector systems and access to international distributors. Its position is strongest where customers need a specialist supplier and a system adapted to local workflow rather than a broad enterprise-imaging contract. Long-term growth depends on maintaining regulatory coverage and responsive service across geographically dispersed installations.

Spectrum Dynamics Medical

Spectrum Dynamics develops digital CZT-based SPECT platforms, including the D-SPECT cardiac series and VERITON 360-degree SPECT/CT architecture. In January 2025, Florida Theranostics installed a VERITON-CT 400, described as the first such system in the southeastern United States. The 12-detector design moves close to the patient and targets high-sensitivity 3D imaging, including theranostic applications. Spectrum’s differentiation comes from detector geometry, digital imaging and quantitative software, though the VERITON platform sits at the advanced compact end of the market rather than the handheld category.

Serac Imaging Systems

Serac Imaging Systems is developing Seracam, a portable hybrid gamma-optical camera intended to bring high-resolution molecular imaging to the bedside. The system overlays gamma information with an optical view of the same anatomical area. Clinical testing began at The Ohio State University Wexner Medical Center in 2023, examining applications that include thyroid, bone, renal, infection, lymphatic and sentinel-node imaging. The company’s opportunity is substantial if portability translates into validated bedside workflows, but Seracam remains an investigational product until the relevant regulatory clearances are obtained.

Recent Market Developments

• In January 2025, Florida Theranostics and Spectrum Dynamics Medical announced that patient scanning had begun on a newly installed VERITON-CT 400 in Jupiter, Florida. The installation demonstrates how compact digital SPECT/CT is moving into specialized theranostic centers that require lesion localization, quantitative imaging and post-treatment assessment.
• In March 2025, Spectrum Dynamics appointed Tomer Gabay as chief executive officer. The leadership change followed his tenure as the company’s chief financial officer and placed commercial growth, new markets and product strategy under an executive with operating and finance experience.
• In August 2024, Spectrum Dynamics Medical and DeepDense Medical entered a partnership focused on artificial intelligence for cardiac and spine imaging and treatment. The collaboration signals a wider shift from hardware-only competition toward reconstruction, interpretation support and workflow software.

Strategic Takeaways

• The market is forecast to add USD 83.90 million between 2025 and 2035, with growth concentrated in solid-state, application-specific and bedside-capable systems.
• Triple-head cameras control 43.5% of current revenue because high-throughput cardiac imaging provides a clear utilization and payback case.
• Handheld cameras hold 13% of revenue but offer the strongest expansion path in surgical localization and small-field imaging, provided clinical evidence and regulatory clearance support routine use.
• North America’s 38.4% share reflects mature nuclear cardiology and flexible financing, while Asia-Pacific’s faster growth depends on hospital capacity, isotope access and local service networks.
• Radioligand therapy creates demand for flexible nuclear imaging, but only cameras with suitable energy range, sensitivity and quantitative validation can capture this opportunity.
• Leasing, rental and managed-service models can overcome capital resistance, yet sustainable adoption still requires sufficient procedure volume and reimbursement.
• Vendors that integrate detector performance with software, training, uptime guarantees and room-planning support will compete more effectively than hardware-only suppliers.

Why Purchase the Report?

• To visualize the global mobile gamma cameras market segmentation based on product type, indication, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analysing trends and co-development.
• Excel data sheet with numerous data points of mobile gamma cameras market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global mobile gamma cameras market report would provide approximately 77 tables, 79 figures and 287 Pages.

Target Audience

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies